MUCOFLUX SYRUP 80 mg10 ml

Држава: Сингапур

Језик: Енглески

Извор: HSA (Health Sciences Authority)

Активни састојак:

CYCLIDROL

Доступно од:

PHARMLINE MARKETING PTE. LTD.

АТЦ код:

R05CB

Дозирање:

80 mg/10 ml

Фармацеутски облик:

SYRUP

Састав:

CYCLIDROL 80 mg/10 ml

Пут администрације:

ORAL

Тип рецептора:

General Sale List

Произведен од:

Laboratorio Farmacologico Milanese S.r.l.

Статус ауторизације:

ACTIVE

Датум одобрења:

1989-06-03

Информативни летак

_Tipo materiale_
_Fustella/Formato_
_Tipo_
_Lingua_
_Codice_
_Codice ROTTAPHARM_
_Corpo testo_
_Data impianto_
_N. colori_
_1a Bozza_
_2a Bozza_
_3a Bozza_
_4a Bozza_
_5a Bozza_
_6a Bozza_
_Colori 1_
_DATA_
_DATA_
_DATA_
_DATA_
_DATA_
_DATA_
_Colori 2_
_Colori 3_
_Colori 4_
_Colori 5_
_Colori 6_
_Colori 7_
_Descrizione:_
Cod. 00004/1
105 X 150
19-05-2011
VENDITA
SINGAPORE
7CIS250E1
CIMU7P/A-2126
19/05/2011
FOGLIO ILL.
MUCOFLUX
1
NERO
FRONTE
The active substance of MUCOFLUX is cyclidrol (sobrerol), a synthetic compound chemically defined as: 
D,L-trans-1-methyl-4-(2-hydroxy-isopropyl)-cyclohex-1,2-en-6-ol.
Cyclidrol lowers the viscosity of mucous, favouring the expulsion of mucous clusters from the respiratory 
tract. It does not affect the alveolar surfactant or the ciliary movements of the bronchotracheal mucosa. 
It has no bronchoconstrictory effects.
Because of these properties cyclidrol is an effective agent in all those disorders where the respiratory tract 
is obstructed or overloaded by an excess of mucous, that hinders the
normal flow of air.
MUCOFLUX has therefore two main actions:
1. CLEANSING, since it allows and facilitates the removal of mucous
and mucopurulent secretions.
2. EUPNEIC, since it improves the respiratory parameters.
INDICATIONS
Acute and chronic disorders of the respiratory tract with increased or stagnant bronchial secretion (phlegm).
Acute and chronic bronchitis, bronchiolitis, bronchial pneumonia, particularly if associated with asthma, 
emphysema, bronchiectasis.
Pulmonary disorders due to cystic fibrosis.
Rhynopharyngitis, acute and chronic laryngotracheitis, sinusitis, pre- and post -surgical cleansing treatment 
of the respiratory tract.
Coadjuvant in the treatment of tuberculosis.
MUCOFLUX may safely be combined with antibiotics.
RECOMMENDED DOSAGE
ADULTS:
capsules: 
2 capsules twice daily for 2 weeks or longer, according to medical
prescription.
syrup: 
1-2 measurefuls (10-20

Карактеристике производа

V1 Mar 2022
Colours
Non-Print
Colours
Date:
Time:
Equate CMYK
with
Dimensions
Main Font
Body Text Size
Min Text Size used
Page Count
No. of colours
Pharma Code
Viatris SAP No.
Vendor Job No.
Artwork Proof No.
Client Market
Keyline/Drawing No.
Barcode Info
Description
Component Type
TrackWise/GLAMS Job No
.
MA No
.
Packing Site/Printer
Superseded Supplier Code
Sign-offs
3D Render ID
New Supplier Code
Black
Keyline
07 JULY 2022
12:30
MUCOFLUX, 80 mg/10 ml, Bottle 60 ml
Leaflet (Insert)
N.A.
2765701
SG2213211
N.A.
N.A.
1
1 of 2
8 pt
8 pt
2765701
2
SIN03031P
Singapore
Laboratorio Farmacologico
Milanese Srl (Caronno - IT)
N.A.
7CIS250E2
N.A.
Helvetica Neue LT Std
N.A.
105x160 mm
CIMU7PA_2126
The
active
substance
of
MUCOFLUX
is
cyclidrol
(sobrerol),
a synthetic compound chemically defined as: D,L-trans-1-methyl-4-
(2-hydroxy-isopropyl)-cyclohex-1,2-en-6-ol.
Cyclidrol lowers the viscosity of mucus, favouring the expulsion of
mucous clusters from the respiratory tract. It does not affect the
alveolar surfactant or the ciliary movements of the bronchotracheal
mucosa. It has no bronchoconstrictory effects.
Because of these properties cyclidrol is an effective agent in all
those
disorders where the respiratory tract is obstructed or overloaded by
an excess of mucus, that hinders the normal flow of air.
MUCOFLUX has therefore two main actions:
1. CLEANSING, since it allows and facilitates the removal of
mucous and mucopurulent secretions.
2. EUPNEIC, since it improves the respiratory parameters.
INDICATIONS
Acute and chronic disorders of the respiratory tract with increased
or stagnant bronchial secretion (phlegm).
Acute and chronic bronchitis, bronchiolitis, bronchial pneumonia,
particularly if associated with asthma, emphysema, bronchiectasis.
Pulmonary disorders due to cystic fibrosis.
Rhynopharyngitis, acute and chronic laryngotracheitis, sinusitis,
pre- and post-surgical cleansing treatment of the respiratory tract.
Coadjuvant in the treatment of tuberculosis.
MUCOFLUX may safely be combined with antibiotics.
RECOMMENDE